메뉴 건너뛰기
Neurology
Volumn 82, Issue 10, 2014, Pages 824-825
Feasibility of Huntington disease trials in the disease prodrome
Author keywords

[No Author keywords available]
Indexed keywords

ALZHEIMER DISEASE; BRAIN SIZE; DEGENERATIVE DISEASE; EDITORIAL; HUNTINGTON CHOREA; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STUDY DESIGN;
EID: 84898751642     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000197     Document Type: Editorial
Times cited : (3)
References (10)
  • 1
    • 84898712203 scopus 로고    scopus 로고
    • PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
    • Rosas HD, Doros G, Gevorkian S, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 2014;82:850-857.
    • (2014) Neurology , vol.82 , pp. 850-857
    • Rosas, H.D.1    Doros, G.2    Gevorkian, S.3
  • 2
    • 48249114740 scopus 로고    scopus 로고
    • Detection of Huntington's disease decades before diagnosis: The Predict-HD study
    • Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008; 79:874-880.
    • (2008) J Neurol Neurosurg Psychiatry , vol.79 , pp. 874-880
    • Paulsen, J.S.1    Langbehn, D.R.2    Stout, J.C.3
  • 3
    • 83555173501 scopus 로고    scopus 로고
    • Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: Analysis of 24 month observational data
    • Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11: 42-53.
    • (2012) Lancet Neurol , vol.11 , pp. 42-53
    • Tabrizi, S.J.1    Reilmann, R.2    Roos, R.A.3
  • 4
    • 23844525922 scopus 로고    scopus 로고
    • Huntington's disease genetics
    • Myers RH. Huntington's disease genetics. NeuroRx 2004; 1:255-262.
    • (2004) NeuroRx , vol.1 , pp. 255-262
    • Myers, R.H.1
  • 5
    • 84882804053 scopus 로고    scopus 로고
    • The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease
    • Hooper M, Grill JD, Rodriguez-Agudelo Y, et al. The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease. Contemp Clin Trials 2013;36:256-262.
    • (2013) Contemp Clin Trials , vol.36 , pp. 256-262
    • Hooper, M.1    Grill, J.D.2    Rodriguez-Agudelo, Y.3
  • 6
    • 78650031174 scopus 로고    scopus 로고
    • Huntington's disease: From molecular pathogenesis to clinical treatment
    • Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10:83-98.
    • (2011) Lancet Neurol , vol.10 , pp. 83-98
    • Ross, C.A.1    Tabrizi, S.J.2
  • 7
    • 84858074593 scopus 로고    scopus 로고
    • CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
    • COHORT Study of the HSG
    • Lee JM, Ramos EM, Lee JH, et al; COHORT Study of the HSG. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 2012;78:690-695.
    • (2012) Neurology , vol.78 , pp. 690-695
    • Lee, J.M.1    Ramos, E.M.2    Lee, J.H.3
  • 8
    • 38949116255 scopus 로고    scopus 로고
    • Living at risk: Concealing risk and preserving hope in Huntington disease
    • Quaid KA, Sims SL, Swenson MM, et al. Living at risk: concealing risk and preserving hope in Huntington disease. J Genet Couns 2008;17:117-128.
    • (2008) J Genet Couns , vol.17 , pp. 117-128
    • Quaid, K.A.1    Sims, S.L.2    Swenson, M.M.3
  • 9
    • 84886797143 scopus 로고    scopus 로고
    • A review of quality of life after predictive testing for an earlier identification of neurodegenerative diseases
    • Paulsen JS, Nance M, Kim JI. A review of quality of life after predictive testing for an earlier identification of neurodegenerative diseases. Prog Neurobiol 2013;110: 2-28.
    • (2013) Prog Neurobiol , vol.110 , pp. 2-28
    • Paulsen, J.S.1    Nance, M.2    Kim, J.I.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.